NEWTON, Mass., December 29, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER) is focused on acquiring, developing and commercializing therapeutics for serious rare and life-threatening diseases A pharmaceutical company with significant untreated disease. Nasdaq Stock Market LLC today formally confirmed to Acer that Acer has complied with the $35 million market value requirement for listed securities and has met all other criteria necessary to remain listed on the Nasdaq Capital Market. announced that it had notified Therefore, the listing issue is now closed and the hearings scheduled prior to the Nasdaq Hearings Panel have been cancelled.
About Acer Therapeutics
Acer is a pharmaceutical company focused on acquiring, developing and commercializing treatments for serious and life-threatening diseases with significant unmet medical need. In the US, OLPRUVA™ (sodium phenylbutyrate) is indicated for the treatment of urea cycle disorders (UCD) with deficiency in carbamyl phosphate synthase (CPS), ornithine transcarbamylase (OTC), or argininosuccinate synthase (AS) Approved. Acer also has a pipeline of investigational drug candidates for rare and life-threatening diseases. ACER-801 (osanetant) is used to treat induced vasomotor symptoms (iVMS) and post-traumatic stress disorder (PTSD). EDSIVO™ (Celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with confirmed collagen type III (COL3A1) mutations. ACER-2820 (Emetine) is a host-directed therapy against a variety of viruses including cytomegalovirus, Zika virus, dengue fever, Ebola and COVID-19. For more information, please visit www.acertx.com.
Acer Therapeutics Co., Ltd.